Compare ONCY & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONCY | CING |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | Canada | United States |
| Employees | N/A | 13 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.0M | 93.1M |
| IPO Year | 2002 | N/A |
| Metric | ONCY | CING |
|---|---|---|
| Price | $0.91 | $5.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.33 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 670.1K | 658.7K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,505.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $3.20 |
| 52 Week High | $1.51 | $11.89 |
| Indicator | ONCY | CING |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 42.16 |
| Support Level | $0.90 | $3.62 |
| Resistance Level | $1.08 | $6.64 |
| Average True Range (ATR) | 0.06 | 0.71 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 56.50 | 9.34 |
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.